about
PARPs and the DNA damage responseThe NER proteins XPC and CSB, but not ERCC1, regulate the sensitivity to the novel DNA binder S23906: implications for recognition and repair of antitumor alkylators.Resistance mechanisms associated with altered intracellular distribution of anticancer agents.Catalytic topoisomerase II inhibitors in cancer therapy.Unexpected talaroenamine derivatives and an undescribed polyester from the fungus Talaromyces stipitatus ATCC10500.Talaroketals A and B, unusual bis(oxaphenalenone) spiro and fused ketals from the soil fungus Talaromyces stipitatus ATCC 10500.BRCA2 is needed for both repair and cell cycle arrest in mammalian cells exposed to S23906, an anticancer monofunctional DNA binder.Antimicrobial Oligophenalenone Dimers from the Soil Fungus Talaromyces stipitatus.What histone code for DNA repair?Dual inhibition of ATR and ATM potentiates the activity of trabectedin and lurbinectedin by perturbing the DNA damage response and homologous recombination repair.DNA alkylation damage and autophagy induction.Emergence of drug tolerance in cancer cell populations: an evolutionary outcome of selection, nongenetic instability, and stress-induced adaptation.Genotype- or Phenotype-Targeting Anticancer Therapies? Lessons from Tumor Evolutionary Biology.5-Fluorouracil and its active metabolite FdUMP cause DNA damage in human SW620 colon adenocarcinoma cell line.Mitosis-specific MPM-2 phosphorylation of DNA topoisomerase IIalpha is regulated directly by protein phosphatase 2A.Acquired irinotecan resistance is accompanied by stable modifications of cell cycle dynamics independent of MSI status.Down-regulation of DNA topoisomerase IIalpha leads to prolonged cell cycle transit in G2 and early M phases and increased survival to microtubule-interacting agents.Modeling the effects of space structure and combination therapies on phenotypic heterogeneity and drug resistance in solid tumors.ATP-dependent chromatin remodeling and histone acetyltransferases in 5-FU cytotoxicity in Saccharomyces cerevisiae.The catalytic activities of DNA topoisomerase II are most closely associated with the DNA cleavage/religation steps.EGFR- and VEGF(R)-targeted small molecules show synergistic activity in colorectal cancer models refractory to combinations of monoclonal antibodies.Combinations of Bevacizumab and Erlotinib Show Activity in Colorectal Cancer Independent of RAS Status.Multifaceted Study on a Cytochalasin Scaffold: Lessons on Reactivity, Multidentate Catalysis, and Anticancer PropertiesIntramolecular Aryne-Furan Cycloadditions for the Synthesis of Anticancer NaphthalimidesDipyridamole as a new drug to prevent Epstein-Barr virus reactivationEpstein-Barr Virus BALF0 and BALF1 Modulate AutophagyDetection of IgG directed against a recombinant form of Epstein-Barr virus BALF0/1 protein in patients with nasopharyngeal carcinoma
P50
Q26859010-9E1D5EFD-B76A-4086-8961-40A4289216FFQ30981252-C277EB14-7AFC-41CC-975D-CF7FF4883585Q33876883-615A0FE4-6F12-4541-BECD-6C184A2DB7F4Q35187762-B7144C94-5333-4924-AF80-ED1E192984B6Q35781370-EB8AAB6C-62A6-463B-B0E6-AACE7B09A7DCQ35912465-7E61830D-B176-4FBF-9CDC-FED9C66BC4F4Q36188973-4C43A078-B92D-4F6C-B40D-54DA4039FDEBQ36223255-8EC5F583-F64D-42BE-9F25-EFB4767AF80FQ37093152-4C40A5CB-54A5-4363-8412-795FC7C83DBAQ37295535-45043B9D-0787-4E1E-94E7-BC41F9F0A0F3Q38122962-B2A86EA5-6BE8-458A-95EE-73220003491CQ38915812-73573098-C2C9-46C7-A3D3-20BA28674AC4Q38944459-AEA08BBE-92E6-4132-9AC7-C9067A6E12D0Q39900556-1DFB39C0-0465-4201-8C6C-791E9AB0D07DQ40185092-1A64331E-0AD0-4825-AA47-AD84BBF3F77DQ42436505-4356B268-586B-4A14-AFE9-65D8C3D13D39Q46533431-0AF799D7-28D8-4E52-84AE-D876416042DEQ50998666-7CEC30DB-3057-4ABB-8EFF-E96C2873DC4CQ51005482-C4EDAF65-0D9D-49E4-AC93-CB348628A7CDQ54078589-8219B066-AA9C-4EB1-8378-FA4FFB3D25C5Q54564313-C2B719CD-78B2-4CFE-BDF6-454C797EF35AQ54982645-F60368DD-8306-47DB-993B-D4EA2117C06AQ57975244-0D62E411-6BC8-48DB-BEF5-3A9F4DCD01AEQ88215488-DB72F39C-848B-4C57-BA55-CCED35761520Q90456518-A892BCF8-E07A-41A7-A898-63E7B2E5FF10Q91551596-8BADDA40-9FFB-41E5-8E38-C2FA5EC3B860Q92406074-E5BD70CF-95AA-475A-861D-9D0735DF767C
P50
description
researcher ORCID ID = 0000-0002-7419-7518
@en
wetenschapper
@nl
name
Alexandre Escargueil
@ast
Alexandre Escargueil
@en
Alexandre Escargueil
@es
Alexandre Escargueil
@nl
type
label
Alexandre Escargueil
@ast
Alexandre Escargueil
@en
Alexandre Escargueil
@es
Alexandre Escargueil
@nl
prefLabel
Alexandre Escargueil
@ast
Alexandre Escargueil
@en
Alexandre Escargueil
@es
Alexandre Escargueil
@nl
P106
P1153
6507260851
P31
P496
0000-0002-7419-7518